8-K: Atossa Therapeutics Updates on (Z)-Endoxifen Progress

Atossa Therapeutics, Inc. provided a corporate presentation detailing the clinical progress, market opportunity, and financial position of its lead drug candidate, (Z)-endoxifen, for breast cancer.

Summary

• Atossa Therapeutics is developing (Z)-endoxifen for a multi-billion dollar market opportunity in estrogen receptor positive (ER+) breast cancer, covering both prevention and treatment.
• (Z)-endoxifen has demonstrated broad utility across the breast cancer paradigm, including prevention (recurrence, DCIS, high-risk dense breast tissue) and treatment (neoadjuvant, metastatic).
• In an ongoing neoadjuvant clinical study (EVANGELINE), (Z)-endoxifen showed promising early efficacy with one complete response and multiple partial responses, and a 4-week Ki-67 <10% response rate generally above 85%.
• Previous clinical studies in metastatic breast cancer demonstrated promising anti-tumor activity, with a median Progression-Free Survival (PFS) of 7.2 months for (Z)-endoxifen compared to 2.4 months for tamoxifen (HR=0.42, P=0.002) in CDK4/6 inhibitor naive patients.
• The KARISMA prevention trial showed that a 1 mg dose of (Z)-endoxifen reduced mammographic breast density (MBD) by 17.3 percentage points (p<0.01) with no significant differences in adverse events compared to placebo.
• The company maintains a strong financial position with $57.9 million in cash as of June 30, 2025, providing over a year of working capital and zero debt.
• FDA feedback affirmed the strategic approach for (Z)-endoxifen, confirming existing clinical and nonclinical data are sufficient for initiating Phase 2 monotherapy and agreeing on combination strategies.
• Key upcoming milestones include an IND filing for Project Optimus (metastatic breast cancer) in Q4 2025 and a 505(b)(2) NDA filing for prevention in 2026.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to promising clinical trial results across multiple indications, strong financial health with no debt, positive FDA feedback, and a clear strategic path with upcoming milestones. The drug's differentiation and market opportunity also contribute to the strong positive outlook.

Positives

• Demonstrated broad utility and best-in-class potential for (Z)-endoxifen across the breast cancer paradigm, including prevention and treatment.
• Promising early efficacy results in neoadjuvant settings, including complete and partial responses and high Ki-67 suppression rates (>85%).
• Significant improvement in Progression-Free Survival (PFS) in metastatic breast cancer patients (7.2 months vs. 2.4 months for tamoxifen, P=0.002).
• Positive results in the KARISMA prevention trial, showing a 17.3 percentage point reduction in mammographic breast density (p<0.01) at a low dose with good tolerability.
• Strong financial position with $57.9 million in cash as of June 30, 2025, providing over a year of runway and zero debt.
• Positive FDA feedback, confirming sufficiency of existing data for Phase 2, alignment with Project Optimus, and agreement on combination therapy strategies.
• Robust and growing intellectual property portfolio with broad protections in the U.S. and globally.
• (Z)-endoxifen is highly differentiated from current standard of care agents, being 100-fold more potent than tamoxifen and inhibiting ESR1 mutants.

Negatives

• The presentation is a corporate update and does not highlight any specific negative financial or operational outcomes.
• One serious adverse event (hemorrhagic ovarian cyst) was reported related to the study drug in the EVANGELINE trial, though overall tolerability was good.

Risks

• Actual results and events may differ significantly from results and events discussed in forward-looking statements.
• Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Risk Factors in the company's Annual Reports on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission.
• The company may not yet have received clearance from the FDA or any other regulatory agency for some of the products described in this presentation.

Future Outlook

The company anticipates significant progress with (Z)-endoxifen, including an IND filing for metastatic breast cancer in Q4 2025, a 505(b)(2) NDA filing for prevention in 2026, and continued clinical trial updates and regulatory readouts for both early disease and metastatic settings. The goal is to address significant unmet medical needs in ER+/HER2metastatic breast cancer and drive shareholder value.

Management Comments

• Management believes (Z)-endoxifen has best-in-class potential across the breast cancer paradigm.
• The company's clinical strategy for neoadjuvant trials aims to understand (Z)-endoxifen's value proposition quickly through fast biomarker readouts.
• The FDA feedback significantly narrows the strategic focus, enabling efficient clinical execution.
• The metastatic program provides the fastest path to market and highest probability of success, strengthening the foundation for expansion into earlier-stage disease settings.

Industry Context

The announcement highlights (Z)-endoxifen's potential to address significant unmet needs in the rapidly growing estrogen receptor positive breast cancer market, where current endocrine therapies face challenges such as patient non-response, discontinuation, and lack of benefit from existing treatments. The drug is positioned as a novel, next-generation anti-estrogen with superior anti-tumor activity and a favorable safety profile compared to existing standard-of-care agents like tamoxifen, aromatase inhibitors, and fulvestrant. Its potential as a preferred combination partner for CDK4/6 inhibitors aligns with current trends in combination therapies for breast cancer.

Comparison to Industry Standards

• (Z)-endoxifen demonstrated superior anti-tumor activity compared to tamoxifen and aromatase inhibitors in preclinical models (MCF7AC1 and MCF7LR).
• In a Phase 2 trial, (Z)-endoxifen achieved a median Progression-Free Survival (PFS) of 7.2 months in CDK4/6 inhibitor naive metastatic patients, significantly outperforming tamoxifen's 2.4 months PFS (HR=0.42, P=0.002).
• Preclinical data suggests (Z)-endoxifen is 100-fold more potent in anti-estrogen activity compared to tamoxifen.
• Unlike current endocrine therapies which are generally cytostatic, (Z)-endoxifen has shown tumor shrinkage and disease regression.
• (Z)-endoxifen inhibits clinically relevant ESR1 mutants, an acquired resistance mechanism to aromatase inhibitors, offering a potential advantage over existing treatments.
• The drug's potential to be a preferred endocrine combination partner for CDK4/6 inhibitors (e.g., IBRANCE, KISQALI, VERZENIO) suggests an improved efficacy and safety profile compared to current combinations.

Stakeholder Impact

• **Shareholders:** Potential for increased shareholder value through clinical milestones, market expansion, and efficient regulatory pathways.
• **Patients:** Potential for new, more effective, and better-tolerated treatment and prevention options for ER+ breast cancer, addressing significant unmet medical needs.
• **Employees:** Continued employment and potential growth opportunities as the company advances its clinical programs.
• **Regulatory Authorities:** Continued engagement with the FDA to ensure adherence to guidance and facilitate potential approvals.

Next Steps

• Finalize IND Submission for Project Optimus (metastatic breast cancer) in Q4 2025.
• Initiate a dose-ranging study for Project Optimus in Q4 2025.
• Announce trial specifics for Project Optimus, including patient populations and combination regimens.
• Initiate clinical study for Project Optimus following IND acceptance.
• File a 505(b)(2) NDA for Prevention in 2026.
• Continue regulatory readouts for early disease indications.
• Provide updates on the Karisma prevention trial and Evangeline trial (reframed as clinical MoA study).
• Conduct the I-SPY trial to validate (Z)-endoxifen's combination strategy with CDK4/6 inhibitors.

Key Dates

Recommendation

The company presents a compelling case for (Z)-endoxifen with strong clinical data showing superior efficacy compared to existing treatments in multiple breast cancer settings, including significant PFS improvement in metastatic disease and positive results in prevention. The positive FDA feedback de-risks the regulatory pathway, and the robust financial position with zero debt provides stability. Upcoming milestones, particularly the IND filing in Q4 2025 and NDA filing in 2026, represent significant catalysts for value creation in a multi-billion dollar market. These factors suggest a strong growth trajectory and potential for substantial returns for investors.

Keywords

Atossa Therapeutics, Z-endoxifen, Breast Cancer, ER+ Breast Cancer, Neoadjuvant, Metastatic Breast Cancer, Breast Cancer Prevention, Oncology, Clinical Trials, FDA, Biotechnology, Pharmaceuticals